New combo therapy aims to halt spread of aggressive breast cancer

NCT ID NCT06492759

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether adding high-dose radiation to standard immunotherapy (pembrolizumab) and chemotherapy can help control metastatic triple-negative breast cancer that is PD-L1 positive. About 29 participants with at least two sites of metastatic disease will receive the combination. The main goal is to see if this approach improves the time until the cancer progresses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pembrolizumab (immunotherapy) plus chemotherapy (paclitaxel, nab-paclitaxel, carboplatin, gemcitabine) and high-dose radiation therapy
What this could lead to
If successful, this combination could improve how long the cancer is kept under control in patients with metastatic triple-negative breast cancer.
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply broadly. The combination of radiation, immunotherapy, and chemotherapy can cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.